Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NATALIE: Cabozantinib in Metastatic Pheochromocytoma and Paraganglioma
NCT02302833Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2015
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in pheochromocytoma, Paraganglioma (PGL), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2015; status: completed.
02
Drugs
cabozantinib
03
Conditions
pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT02302833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02302833.